Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance.

Wilson CS, Medeiros LJ, Lai R, Butch AW, McCourty A, Kelly K, Brynes RK.

Mod Pathol. 2001 Sep;14(9):886-91.

2.

The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.

Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A.

Cancer Treat Rev. 2009 Dec;35(8):662-7. doi: 10.1016/j.ctrv.2009.08.006. Epub 2009 Sep 15. Review.

PMID:
19758759
3.

Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.

Valkov NI, Sullivan DM.

Semin Hematol. 1997 Oct;34(4 Suppl 5):48-62. Review.

PMID:
9408961
4.

Clinical resistance to topoisomerase-targeted drugs.

Dingemans AM, Pinedo HM, Giaccone G.

Biochim Biophys Acta. 1998 Oct 1;1400(1-3):275-88. Review.

PMID:
9748627
5.

Quantitative cytology in myeloma research.

Barlogie B, Latreille J, Alexanian R, Swartzendruber DE, Smallwood L, Maddox AM, Raber MN, Drewinko B.

Clin Haematol. 1982 Feb;11(1):19-46. Review. No abstract available.

PMID:
6176382

Supplemental Content

Support Center